Clear Scientific, LLC

Clear Scientific, LLC, a for-profit limited liability company and subsidiary of Clear Scientific, Inc., develops pharmaceutical therapeutics and chemical-biological defense formulations for federal agencies as a prime contractor under the Small Business Innovation Research program and through cooperative agreements with the National Institutes of Health. The company is based in Cambridge, Massachusetts and competes exclusively under small-business set-asides on defense contracts and as an unrestricted applicant on NIH grants.

Clear Scientific's contract footprint centers on chemical and biological defense research under the Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense, which accounts for 11 awards with $8.28 billion combined potential value—nearly all of the vendor's federal contract authority. These awards span SBIR Phase I and Phase II actions focused on antimicrobial formulations, wound-treatment gauze for chemical-threat environments, and related pharmaceutical development. Representative contract work includes a $1.099 million SBIR Phase II Base Year award (August 2023, ultimate completion August 2025) for developing a stable antimicrobial formulation of scopolamine for multi-dose vials; a $999.888 million SBIR Phase II award (September 2022, ultimate completion October 2024) for chemical-biological defense research; and a $1.096 million Cost Plus Fixed Fee contract (August 2022, ultimate completion August 2024) from the Defense Threat Reduction Agency for research and development of chemical-resistant wound-treatment gauze. A single $111 thousand purchase order from the Defense Health Agency (September 2022, ultimate completion September 2024) covered drug formulation, quality assurance/quality control, method development, and sample analysis for pharmaceutical and medical programs. All contract work is performed at Clear Scientific's Cambridge facility.

The vendor's grant portfolio with the National Institute on Drug Abuse (NIDA, part of the National Institutes of Health) represents nine awards with substantially lower individual values but significant clinical development scope. The vendor is recipient on four cooperative agreements for clinical-stage therapeutic development: a $3 million cooperative agreement (August 2026, ultimate completion July 2028) for a Phase 2A clinical study of CS-1103 for methamphetamine intoxication treatment; a $1.099 million cooperative agreement (August 2023, ultimate completion June 2026) for clinical development of CS-1103 for methamphetamine intoxication; and a second cooperative agreement (September 2023, ultimate completion August 2026) addressing CS-1103 development for synthetic opioid reversal. The vendor also holds three project grants from NIDA: one for reversal-agent development for fentanyl and xylazine co-use (August 2024, ultimate completion July 2026); one for oral therapeutic development to treat stimulant intoxication (September 2022, ultimate completion March 2023); and one for multi-substance overdose reversal (July 2022, ultimate completion December 2022). All grant work is conducted in Cambridge.

Activity has been episodic, with five awards in 2021 declining to one in 2024 and resuming with one award in August 2026. Only one award is set to complete within the next twenty-four months, limiting near-term recompete exposure. The vendor operates exclusively as a prime contractor with no subcontract footprint across the source data. Clear Scientific's technology platform centers on small-molecule sequestrants—compounds that bind and rapidly clear drugs of abuse from the body while accelerating their elimination via renal filtration—with applications spanning methamphetamine, fentanyl, xylazine, and polysubstance overdose reversal. The vendor's chemical-defense work on scopolamine formulation and chemical-resistant wound treatment represents a distinct but lower-dollar capability stream alongside its therapeutic-development focus.